CureVac (NASDAQ:CVAC - Get Free Report) shares rose 9.1% during trading on Tuesday . The company traded as high as $3.12 and last traded at $3.19. Approximately 481,439 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 885,243 shares. The stock had previously closed at $2.92.
Analyst Ratings Changes
Separately, JMP Securities reaffirmed a "market outperform" rating and set a $16.00 price objective on shares of CureVac in a research report on Friday, February 14th.
Get Our Latest Stock Analysis on CureVac
CureVac Price Performance
The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company has a market cap of $707.46 million, a P/E ratio of 5.75 and a beta of 2.53. The firm's fifty day moving average is $3.66 and its two-hundred day moving average is $3.20.
Hedge Funds Weigh In On CureVac
A number of hedge funds have recently made changes to their positions in the business. Barclays PLC purchased a new stake in CureVac during the 3rd quarter valued at approximately $67,000. Public Employees Retirement System of Ohio bought a new position in shares of CureVac during the 3rd quarter valued at about $91,000. Jane Street Group LLC grew its position in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock valued at $235,000 after purchasing an additional 55,867 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock worth $162,000 after purchasing an additional 4,425 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in CureVac during the third quarter valued at approximately $35,000. Institutional investors own 17.26% of the company's stock.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
